Survivin-Derived Peptide LYLKNYRIA is a survivin-derived peptide from BIRC5, a member of the inhibitor-of-apoptosis protein family and a widely studied tumor-associated antigen. Survivin as a Tumor-Antigen Research Target Survivin is expressed at high levels in many proliferating and malignant cells and is associated with cell division and inhibition of apoptosis. Because of this expression pattern, survivin-derived peptides have been investigated as targets for T-cell immunology, peptide vaccination, antigen-presentation assays, and tumor-immunology research. LYLKNYRIA Sequence Sequence: LYLKNYRIA Reported position/context: within the QP19 survivin region LYLKNYRIA is contained within a publicly reported survivin-derived region used for MHC class I/II peptide-vaccine design; the isolated 9-mer can be used as a defined sequence fragment. Potential Research Applications - Survivin peptide-vaccine research
- T-cell stimulation assays
- MHC-binding studies
- Antigen presentation research
- ELISpot and cytokine-response assays
- Tumor immunology
Peptide-MHC restriction and immunogenicity depend on species, MHC allele, experimental system, and peptide formulation. Researchers should select the appropriate peptide and model for their study. References Siegel S, et al. Survivin (BIRC5) peptide vaccine studies and survivin-derived murine MHC class I peptides. Vaccines. 2023;11(3):644.
Public source / publication Andersen MH, et al. Identification of novel survivin-derived CTL epitopes. Cancer Biol Ther. 2004;3(2).
doi: 10.4161/cbt.3.2.611.
Public source / publication Related LifeTein Services Custom Peptide Synthesis
Fluorescent Peptide Labeling
Peptide Click Chemistry and Conjugation
Peptide Carrier Protein Conjugation Research Use Only. Not for human, diagnostic, clinical, or therapeutic use. | 